IDEXX Raises 2026 EPS Guidance to $14.69-$14.94 After Strong Q2 Beat
IDXX is trading near its 52-week low of $518.55 (13% above the low) on elevated volume (2.3× avg).
Summary
IDEXX Laboratories reported Q2 2026 revenue of $1.217 billion and diluted EPS of $4.27, both above expectations, and raised full-year EPS guidance to $14.69-$14.94. Strong cash flow funded nearly $700 million in share repurchases.
Key Events · Earnings and Guidance · IDXX
-
Q2 Revenue and EPS Beat
Revenue grew 9.7% to $1.217 billion; diluted EPS of $4.27 exceeded expectations, driven by 10.3% organic growth in CAG Diagnostics recurring revenue.
-
Full-Year Guidance Raised
Management increased 2026 EPS guidance to $14.69-$14.94, up from prior expectations, citing strong volume and price realization across segments.
-
Gross Margin Expansion
Gross margin improved 140 bps to 64.0%, benefiting from favorable mix shift toward higher-margin consumables and reference lab services, and operational productivity.
-
Operating Cash Flow Surge
H1 2026 operating cash flow reached $613.4 million, up 45% YoY, driven by higher net income and a $77.9 million reduction in cash used for working capital versus the prior year.
Analysis · IDXX · Life Sciences
IDEXX delivered a strong Q2, with revenue up 9.7% and diluted EPS of $4.27 beating expectations. Gross margin expanded 140 basis points to 64%, driven by favorable mix and productivity. Management raised full-year 2026 EPS guidance to $14.69-$14.94, reflecting confidence in sustained demand for companion animal diagnostics. Operating cash flow surged to $613.4 million in the first half, up 45% year-over-year, providing ample capacity for the $692.9 million in share repurchases executed at an average price of $592.41. The company also amended supply agreements with Ortho-Clinical Diagnostics to support SDMA slide packaging, reinforcing its diagnostic menu expansion. With a net debt to EBITDA ratio of just 0.46x and $729 million in available credit, IDEXX has significant financial flexibility to continue returning capital to shareholders while investing in growth.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXX was trading at $588.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.4B. The 52-week trading range was $518.55 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.